Effects of pharmacogenetics on pharmacokinetics and toxicity of doxorubicin in Egyptian breast cancer patients

References

• Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. 2020. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother. 121:109657. doi: 10.1016/j.biopha.2019.109657.
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Saadeh SS, Abu-Nasser M, Abdulelah H, Marie L, Salam M, Ali BA-H, Ibrahim M, Rimawi D. 2018. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther. 11:2091–2096. doi: 10.2147/OTT.S151821.
   PubMed Web of Science ®Google Scholar
• Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, Bukhari N. 2019. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 12(3):728–736. doi: 10.1159/000503095.
   PubMed Web of Science ®Google Scholar
• Azim HA, Elghazawy H, Ghazy RM, Abdelaziz AH, Abdelsalam M, Elzorkany A, Kassem L. 2023. Clinicopathologic features of breast cancer in egypt-contemporary profile and future needs: a systematic review and meta-analysis. J Clin Oncol Glob Oncol. 9:e2200387. doi: 10.1200/GO.22.00387.
   PubMedGoogle Scholar
• Bagdasaryan AA, Chubarev VN, Smolyarchuk EA, Drozdov VN, Krasnyuk II, Liu J, Fan R, Tse E, Shikh EV, Sukocheva OA. 2022. Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy. Cancers (Basel). 14(21):5436. doi: 10.3390/cancers14215436.
   PubMed Web of Science ®Google Scholar
• Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW. 2009. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos. 37(5):1107–1114. doi: 10.1124/dmd.108.024711.
   PubMed Web of Science ®Google Scholar
• Barpe DR, Rosa DD, Froehlich PE. 2010. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci. 41(3–4):458–463. doi: 10.1016/j.ejps.2010.07.015.
   PubMed Web of Science ®Google Scholar
• Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV. 2010. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 102(6):1003–1009. doi: 10.1038/sj.bjc.6605587.
   PubMed Web of Science ®Google Scholar
• Breysse DH, Boone RM, Long CM, Merrill ME, Schaupp CM, White CC, Kavanagh TJ, Schmidt EE, Merrill GF. 2020. Carbonyl reductase 1 plays a significant role in converting doxorubicin to cardiotoxic doxorubicinol in mouse liver, but the majority of the doxorubicinol-forming activity remains unidentified. Drug Metab Dispos. 48(3):187–197. doi: 10.1124/dmd.119.089326.
   PubMed Web of Science ®Google Scholar
• Cui L, Huang J, Zhan Y, Qiu N, Jin H, Li J, Huang H, Li H. 2021. Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy. Life Sci. 276:119392. doi: 10.1016/j.lfs.2021.119392.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365(9472):1687–1717. doi: 10.1016/S0140-6736(05)66544-0.
   PubMed Web of Science ®Google Scholar
• Faraji A, Dehghan Manshadi HR, Mobaraki M, Zare M, Houshmand M. 2016. Association of ABCB1 and SLC22A16 gene polymorphisms with incidence of doxorubicin-induced febrile neutropenia: a survey of Iranian breast cancer patients. PLoS One. 11(12):e0168519. doi: 10.1371/journal.pone.0168519.
   PubMed Web of Science ®Google Scholar
• Forrest GL, Gonzalez B, Tseng W, Li X, Mann J. 2000. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res. 60(18):5158–5164.
   PubMed Web of Science ®Google Scholar
• Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. 2012. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer. 12(1):381. doi: 10.1186/1471-2407-12-381.
   PubMedGoogle Scholar
• Huang Y. 2007. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 26(1):183–201. doi: 10.1007/s10555-007-9050-6.
   PubMed Web of Science ®Google Scholar
• Ibrahim AH, Shash E. 2022. General Oncology Care in Egypt. In: Al-Shamsi HO, Abu-Gheida IH, Iqbal F, Al-Awadhi A, editors. Cancer in the Arab world. Singapore: Springer; p. 41–61. [accessed 2023 Sep 5]. doi: 10.1007/978-981-16-7945-2_4.
   Google Scholar
• Lal S, Sandanaraj E, Wong ZW, Ang PCS, Wong NS, Lee EJD, Chowbay B. 2008. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 99(10):2045–2054. doi: 10.1111/j.1349-7006.2008.00903.x.
   PubMed Web of Science ®Google Scholar
• Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PCS, Figg WD, Lee EJ, Chowbay B. 2007. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics. 8(6):567–575. doi: 10.2217/14622416.8.6.567.
   PubMed Web of Science ®Google Scholar
• Lee NH. 2010. Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. Anticancer Agents Med Chem. 10(8):583–592. doi: 10.2174/187152010794474019.
   PubMed Web of Science ®Google Scholar
• Liutkauskiene S, Grizas S, Jureniene K, Suipyte J, Statnickaite A, Juozaityte E. 2018. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer. 18(1):453. doi: 10.1186/s12885-018-4365-y.
   PubMedGoogle Scholar
• Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, et al. 2005. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun. 333(3):754–762. doi: 10.1016/j.bbrc.2005.05.174.
   PubMed Web of Science ®Google Scholar
• Olson LE, Bedja D, Alvey SJ, Cardounel AJ, Gabrielson KL, Reeves RH. 2003. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res. 63(20):6602–6606.
   PubMed Web of Science ®Google Scholar
• Prieto-Callejero B, Rivera F, Fagundo-Rivera J, Romero A, Romero-Martín M, Gómez-Salgado J, Ruiz-Frutos C. 2020. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. Medicine (Baltimore)).). 99(33):e21695. doi: 10.1097/MD.0000000000021695.
   PubMed Web of Science ®Google Scholar
• Rickham PP. 1964. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J. 2(5402):177. doi: 10.1136/bmj.2.5402.177.
   PubMed Web of Science ®Google Scholar
• Shi S, Chen Y, Luo Z, Nie G, Dai Y. 2023. Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy. Cell Commun Signal. 21(1):61. doi: 10.1186/s12964-023-01077-5.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Giaquinto AN, Jemal A. 2024. Cancer statistics, 2024. CA Cancer J Clin. 74(1):12–49. doi: 10.3322/caac.21820.
   PubMed Web of Science ®Google Scholar
• Tecza K, Pamula-Pilat J, Lanuszewska J, Butkiewicz D, Grzybowska E. 2018. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 9(10):9114–9136. doi: 10.18632/oncotarget.24148.
   PubMedGoogle Scholar
• Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB. 2011. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 21(7):440–446. doi: 10.1097/FPC.0b013e32833ffb56.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. 2003. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 13(3):176–181. doi: 10.1016/S1053-4296(03)00031-6.
   PubMed Web of Science ®Google Scholar
• Varatharajan S, Abraham A, Zhang W, Shaji RV, Ahmed R, Abraham A, George B, Srivastava A, Chandy M, Mathews V, et al. 2012. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol. 68(12):1577–1586. doi: 10.1007/s00228-012-1291-9.
   PubMed Web of Science ®Google Scholar
• Venkatesh P, Kasi A. 2023. Anthracyclines. In: statPearls. Treasure Island (FL): StatPearls Publishing. [accessed 2023 Sep 5]. http://www.ncbi.nlm.nih.gov/books/NBK538187/.
   Google Scholar
• Zaheed M, Wilcken N, Willson ML, O’Connell DL, Goodwin A. 2019. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2(2):CD012873. doi: 10.1002/14651858.CD012873.pub2.
   PubMedGoogle Scholar